THE EUROSDR GEOBIM PROJECT - DEVELOPING CASE STUDIES for the USE of GEOBIM in PRACTICE

Although the use of location-based data (location coupled with semantic information) within Geographical Information Systems (GIS) and from Earth Observation (e.g. satellite) sources has been long established for decision makers, this has only recently been reflected in the construction sector with a more recent move from Computer Aided Design (CAD) to Building Information Modelling. BIM has opened up an additional source of valuable location-based data, with particular focus on the architecture, structural and engineering detail of both buildings and infrastructure projects. As with most if not all location data, while BIM can be used on its own, major benefits are to be derived from integration with other data sources. When this is done with GIS, the result is known as GeoBIM and although there are some similarities between the two, challenges to integration are both technical and non technical, in particular the need for clear case studies to motivate both developers and senior management. There are synergies to be gained from a multi-national, coordinated approach when addressing these challenges, where participants can benefit from each-others' experience and where the needs of users and the National Mapping and Cadastral Agency (NMCA) perspective underpin the research. This paper summarises final outcomes and findings of the EuroSDR GeoBIM research project, which was set up to provide the required multi-national, user-centric collaborative framework, which had as its overall aim the development of best practice guidelines for GeoBIM, and due to its situation within EuroSDR has an NMCA focus. The paper updates information with regard to GeoBIM projects and maturity in the participant countries, and provides an overview of the two case studies developed

Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.

Topoisomerase I inhibitors constitute a new class of anti-cancer agents. Recently, topotecan and irinotecan were registered for clinical use in ovarian cancer and colorectal cancer respectively. Cytotoxicity of topoisomerase I inhibitors is S-phase specific, and in vitro and in vivo studies have suggested that, for efficacy, prolonged exposure might be more important than short-term exposure to high concentration. Clinical development of those topoisomerase I inhibitors that have reached this stage is also focused on schedules aiming to achieve prolonged exposure. In this review, we summarize all published preclinical studies on this topic for topoisomerase I inhibitors in clinical development, namely 20-S-camptothecin, 9-nitro-camptothecin, 9-amino-camptothecin, topotecan, irinotecan and GI147211. In addition, preliminary data on clinical studies concerning this topic are also reviewed. The data suggest that prolonged exposure may indeed be relevant for anti-tumour activity. However, the optimal schedule is yet to be determined. Finally, clinical data are yet too immature to draw definitive conclusions

Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy acid) in human plasma and urine

A sensitive reversed-phase high-performance liquid chromatographic fluorescence method is described for the simultaneous determination of topotecan (I) and the hydrolysed lactone ring-opened product hydroxy acid (II) in plasma and for the determination of I in urine. To 250 μl of plasma, a 750-μl volume of cold methanol was added to stabilize the pH-dependent conversion of I into II. In plasma, the lower limit of quantitation (LLQ) for both compounds was 0.10 ng/ml. The between-day variation for I at the LLQ was 7.1% and for II was 5.5%. Prior to injection, urine samples were acidified with orthophosphoric acid and diluted with phosphate-buffered saline (PBS). In urine, the calibration curve for I was linear in the range of 10 to 250 ng/ml and the LLQ was 10 ng/ml. The assay was developed to enable pharmacological analysis of I, in on-going phase I and II studies, in patients with solid tumors

Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients.

The semisynthetic taxoid docetaxel was investigated in a phase II study in non-chemotherapy pretreated patients with metastatic urothelial cell cancer. Thirty patients (median age 61, range 45-72) were treated with docetaxel 100 mg m(-2) administered as a 1-h infusion every 3 weeks. Of 29 evaluable patients, four achieved a complete response and five a partial response, for an overall response rate of 31%. The median duration of response was 6 months (range 4-51+). A total of 104 cycles were administered. The median number of cycles given was three (range 1-9). Toxic effects of docetaxel mainly consisted of neutropenia, which, however, rarely caused infectious complications (5%). Fluid retention or neuropathy necessitated treatment cessation in two patients. We conclude that docetaxel is an effective agent in urothelial cell cancer, and should be further tested in combination chemotherapy

Geobim for digital building permit process: Learning from a case study in Rotterdam

Among the digitalization processes which are being raised in Europe and in the world, the building permit process is seen as one of the priorities by municipalities, governmental institutions and standardization organizations. However, in current practice, the building permit issuing as well as the integration of geoinformation with BIM (GeoBIM) suffers from a number of complex sub-issues. These issues still remain and prevent the development of successful methodologies. In this paper, the building permit use case is explored within a project in close collaboration with the municipality of Rotterdam. A very specific case study in Rotterdam was selected as a starting point, which allowed us to develop the needed methodology for the implementation of an effective tool. In this paper we highlight the interpretation and formalization of regulation for building height, overhang and tower ratio. While these rules are specific to a zoning plan in Rotterdam, we believe that the methodology and encountered issues in formalizing the rules, applying the rules on delivered models and integrating various data sources (BIM and GIS specifically) are general to most building codes

Possible lack of full cross-resistance of 5HT3 antagonists; a pilot study

We investigated the potential of cross-over to the serotonin receptor (5HT3) antagonist ondansetron after protection failure with tropisetron. Several cases of complete protection were observed. These limited data suggest that there is an indication for retreatment with a different 5HT3 antagonist after an initial failure to another and also stress the need and relevance for comparative studies between 5HT3 antagonists

A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours

The ether lipid miltefosine (hexadecylphosphocholine) was orally given to patients with various tumours in a dose-finding study. All patients initially received a daily total dose of 100 mg, which in the absence of side-effects was increased to 150 mg and further to 200 mg. A total of 54 patients were entered and were evaluable for gastrointestinal toxicity. Nausea and vomiting were found to be dose-limiting; 22% of patients ultimately tolerated a dose of 100 mg, 59% tolerated a dose of 150 mg and 19% tolerated a dose of 200 mg. In addition 30% of patients developed renal dysfunction, which was thought to be related to the drug. No other toxities were observed. For further phase II studies it is recommended that one starts with a dose of 150 mg daily, divided over three administrations